Brief: Supernus Pharmaceuticals Sees FY revenue USD 580-620 million
09/05/2023 21:11
May 9 (Reuters) - Supernus Pharmaceuticals Q1 revenue USD 153.8 million. * Q1 adjusted operating earnings USD 30.5 million * Q1 operating earnings USD 5.2 million * Outlook FY operating earnings USD -30 to -10 million * Outlook FY revenue USD 580-620 million
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing